Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Drobuline SCHEMBL11708442 | 0.98 | ADRB2 (0.54) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| Hydrochloric Acid SCHEMBL11712232 | 0.83 | ADRB2 (0.51) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL12312604 | 0.80 | CYP2D6 (0.50) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| Hydrochloric Acid SCHEMBL11710386 | 0.79 | TAAR1 (0.55) | CYP2D6MEN1KMT2AHIF1A | |
| SCHEMBL4564683 | 0.79 | TSHR (0.64) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL9183624 | 0.79 | TSHR (0.64) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL12312539 | 0.79 | TSHR (0.64) | ADRB2ADRB1ADRB3CYP2D6MEN1 | |
| SCHEMBL11713459 | 0.76 | CYP2D6 (0.57) | ADRB2ADRB1ADRB3CYP2D6HIF1A | |
| Hydrochloric Acid SCHEMBL11716456 | 0.76 | LMNA (0.46) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL20553029 | 0.76 | ADRB2 (0.57) | ADRB2ADRB1ADRB3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4049827-A | Method of treating arrhythmia with diarylbutanolamines | ELI LILLY AND COMPANY (US) | 1977-09-20 | — | — | US | claimed |
| US-4001328-A | ANTIARRHYTHMIA AGENTS, 4,4-DIPHENYL-2-HYDROXY-BUTYLAMINES | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | claimed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-4401832-A | REACTING ALKALI METAL ARYLOXIDE WITH PHENYL-2-OXIRANECARBOXAMIDE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1983-08-30 | — | — | US | disclosed |
| US-4341718-A | α-[(Alkylamino)-methyl]-β-aryloxy-benzeneethanols exhibiting antiarrhythmic activity | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-07-27 | — | — | US | disclosed |
| US-4049827-A | Method of treating arrhythmia with diarylbutanolamines | ELI LILLY AND COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
| US-4001328-A | ANTIARRHYTHMIA AGENTS, 4,4-DIPHENYL-2-HYDROXY-BUTYLAMINES | ELI LILLY AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | ADRB2 334/4885ADRB1 341/4885ADRB3 119/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | ADRB2 334/4885ADRB1 341/4885ADRB3 119/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | ADRB2 334/4885ADRB1 341/4885ADRB3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.